Scientists have developed a new, safe and effective way to infect volunteers with the parasite that causes leishmaniasis and measure the body’s immune response, bringing a vaccine for the neglected tropical disease a step closer.
Alnylam reveals positive Phase III results for rare heart disease drug vutrisiran – Pharmaceutical Technology
RNAi therapeutic, vutrisiran is FDA approved for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTR) in adults and is sold under the brand name
June 24, 2024